Granted Patent
B2
US 12,257,291 · App. 18/656,340 · Granted Mar 25, 2025
Human alpha-galactosidase variants
Inventors:
Nicholas J. Agard (San Francisco, CA); Mathew G. Miller (San Carlos, CA); Xiyun Zhang (Fremont, CA); Gjalt W. Huisman (Redwood City, CA)
Assignee:
Crosswalk Therapeutics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention provides engineered human alpha-galactosidase polypeptides and compositions thereof. The engineered human alpha-galactosidase polypeptides have been optimized to provide improved stability under both acidic (pH<4.5) and basic (pH>7) conditions. The invention also relates to the use of the compositions comprising the engineered human alpha-galactosidase polypeptides for therapeutic purposes.
Claims (19)
1. A recombinant alpha-galactosidase A comprising a polypeptide sequence comprising at least 90% sequence identity to SEQ ID NO: 46, wherein the polypeptide sequence comprises mutations at 316D, 10P, 39E, 44R, 47T, 92H 166P, 206A, 217R, 247D, 261G, 271A, 302K, 3221, 337P, 368A, and 392T.
2. The recombinant alpha galactosidase A of claim 1 , wherein said alpha galactosidase A is SEQ ID NO: 46.
3. The recombinant alpha galactosidase A of claim 1 , wherein said recombinant alpha galactosidase A is derived from a human alpha galactosidase A.
4. The recombinant alpha galactosidase A of claim 1 , wherein said recombinant alpha galactosidase A is a deimmunized alpha galactosidase A.
5. The recombinant alpha galactosidase A of claim 1 , wherein said recombinant alpha galactosidase A exhibits at least one improved property selected from: i) enhanced catalytic activity; ii) increased tolerance to pH 7.4; iii) increased tolerance to pH 4.3; iv) increased tolerance to serum; v) reduced immunogenicity; or vi) enhanced thermostability; or a combination of any of i), ii), iii), iv), v), or vi), as compared to SEQ ID NO: 5.
6. A composition comprising at least one recombinant alpha galactosidase A of claim 1 .
7. A recombinant polynucleotide sequence encoding at least one recombinant alpha galactosidase A of claim 1 , or optionally said polynucleotide sequence is codon optimized.
8. An expression vector comprising the recombinant polynucleotide sequence of claim 7 .
9. The expression vector of claim 8 , wherein said recombinant polynucleotide sequence is operably linked to a control sequence, or optionally, wherein the control sequence is a promoter, or, wherein the promoter is a heterologous promoter.
10. A host cell comprising the expression vector of claim 7 .
11. A method of producing an alpha galactosidase A variant, comprising culturing said host cell of claim 10 , under conditions that said alpha galactosidase A encoded by said recombinant polynucleotide is produced.
12. The method of claim 11 , further comprising recovering said alpha galactosidase A, or optionally purifying said alpha galactosidase A.
13. A pharmaceutical composition for the treatment of Fabry disease, comprising the composition of claim 6 and a pharmaceutically acceptable carrier and/or excipient.
14. The pharmaceutical composition of claim 13 , wherein said composition is suitable for parenteral injection or infusion to a human.
15. A method for treating the symptoms of Fabry disease in a subject, comprising providing a subject having Fabry disease, with the pharmaceutical composition of claim 13 .
16. The method of claim 15 , wherein said symptoms of Fabry disease are ameliorated.
17. The method of claim 16 , wherein said subject is able to eat a diet that is less restricted in its fat content than diets required by subjects exhibiting the symptoms of Fabry disease.
18. The method of claim 15 , wherein said subject is an infant or a child.
19. The method of claim 15 , wherein said subject is an adult or a young adult.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 5, 2024
From: CODEXIS, INC.
To: CROSSWALK THERAPEUTICS, INC.
Reel/Frame 068311/0763 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 2, 2024
From: AGARD, NICHOLAS J.; MILLER, MATHEW G.; ZHANG, XIYUN; HUISMAN, GJALT W.
To: CODEXIS, INC.
Reel/Frame 068164/0481 →
Continuity (6)
Continuation
15529383
Provisional Application
62216452
· Sep 10, 2015
Provisional Application
62095313
· Dec 22, 2014
References Cited (262)
US 5179023A
· Calhoun et al.
· 1993
[cited by applicant]
US 5356804A
· Desnick et al.
· 1994
[cited by applicant]
US 5605793A
· Stemmer
· 1997
[cited by applicant]
US 5811238A
· Stemmer et al.
· 1998
[cited by applicant]
US 5830721A
· Stemmer et al.
· 1998
[cited by applicant]
US 5834252A
· Stemmer et al.
· 1998
[cited by applicant]
US 5837458A
· Minshull et al.
· 1998
[cited by applicant]
US 5928905A
· Stemmer et al.
· 1999
[cited by applicant]
US 6066626A
· Yew et al.
· 2000
[cited by applicant]
US 6083725A
· Selden et al.
· 2000
[cited by applicant]
US 6096548A
· Stemmer
· 2000
[cited by applicant]
US 6117679A
· Stemmer
· 2000
[cited by applicant]
US 6132970A
· Stemmer
· 2000
[cited by applicant]
US 6165793A
· Stemmer
· 2000
[cited by applicant]
US 6180406B1
· Stemmer
· 2001
[cited by applicant]
US 6251674B1
· Tobin et al.
· 2001
[cited by applicant]
US 6277638B1
· Stemmer
· 2001
[cited by applicant]
US 6287861B1
· Stemmer et al.
· 2001
[cited by applicant]
US 6287862B1
· delCardayre et al.
· 2001
[cited by applicant]
US 6291242B1
· Stemmer
· 2001
[cited by applicant]
US 6297053B1
· Stemmer
· 2001
[cited by applicant]
US 6303344B1
· Patten et al.
· 2001
[cited by applicant]
US 6309883B1
· Minshull et al.
· 2001
[cited by applicant]
US 6319713B1
· Patten et al.
· 2001
[cited by applicant]
US 6319714B1
· Crameri et al.
· 2001
[cited by applicant]
US 6323030B1
· Stemmer
· 2001
[cited by applicant]
US 6326204B1
· delCardayre et al.
· 2001
[cited by applicant]
US 6335160B1
· Patten et al.
· 2002
[cited by applicant]
US 6335198B1
· delCardayre et al.
· 2002
[cited by applicant]
US 6344356B1
· Stemmer
· 2002
[cited by applicant]
US 6352859B1
· delCardayre et al.
· 2002
[cited by applicant]
US 6355484B1
· Patten et al.
· 2002
[cited by applicant]
US 6358740B1
· Patten et al.
· 2002
[cited by applicant]
US 6358742B1
· Stemmer
· 2002
[cited by applicant]
US 6365377B1
· Patten et al.
· 2002
[cited by applicant]
US 6365408B1
· Stemmer
· 2002
[cited by applicant]
US 6368861B1
· Crameri et al.
· 2002
[cited by applicant]
US 6372497B1
· Stemmer
· 2002
[cited by applicant]
US 6376246B1
· Crameri et al.
· 2002
[cited by applicant]
US 6379964B1
· delCardayre et al.
· 2002
[cited by applicant]
US 6387702B1
· Stemmer
· 2002
[cited by applicant]
US 6391552B2
· Stemmer
· 2002
[cited by applicant]
US 6391640B1
· Minshull et al.
· 2002
[cited by applicant]
US 6395547B1
· Stemmer
· 2002
[cited by applicant]
US 6406855B1
· Patten et al.
· 2002
[cited by applicant]
US 6406910B1
· Patten et al.
· 2002
[cited by applicant]
US 6413745B1
· Patten et al.
· 2002
[cited by applicant]
US 6413774B1
· Stemmer
· 2002
[cited by applicant]
US 6420175B1
· Stemmer
· 2002
[cited by applicant]
US 6423542B1
· Crameri et al.
· 2002
[cited by applicant]
US 6426224B1
· Crameri et al.
· 2002
[cited by applicant]
US 6436675B1
· Welch et al.
· 2002
[cited by applicant]
US 6444468B1
· Stemmer et al.
· 2002
[cited by applicant]
US 6455253B1
· Patten et al.
· 2002
[cited by applicant]
US 6479652B1
· Crameri et al.
· 2002
[cited by applicant]
US 6482647B1
· Stemmer
· 2002
[cited by applicant]
US 6489146B2
· Stemmer et al.
· 2002
[cited by applicant]
US 6506602B1
· Stemmer
· 2003
[cited by applicant]
US 6506603B1
· Stemmer
· 2003
[cited by applicant]
US 6519065B1
· Colbourne et al.
· 2003
[cited by applicant]
US 6521453B1
· Crameri et al.
· 2003
[cited by applicant]
US 6528311B1
· delCardayre et al.
· 2003
[cited by applicant]
US 6537746B2
· Arnold et al.
· 2003
[cited by applicant]
US 6573098B1
· Stemmer
· 2003
[cited by applicant]
US 6576467B1
· Stemmer
· 2003
[cited by applicant]
US 6579678B1
· Patten et al.
· 2003
[cited by applicant]
US 6586182B1
· Patten et al.
· 2003
[cited by applicant]
US 6602986B1
· Stemmer et al.
· 2003
[cited by applicant]
US 6613514B2
· Patten et al.
· 2003
[cited by applicant]
US 6653072B1
· Patten et al.
· 2003
[cited by applicant]
US 6716631B1
· delCardayre et al.
· 2004
[cited by applicant]
US 6846968B1
· Erwin et al.
· 2005
[cited by applicant]
US 6946296B2
· Patten et al.
· 2005
[cited by applicant]
US 6961664B2
· Selfinov et al.
· 2005
[cited by applicant]
US 6995017B1
· Stemmer
· 2006
[cited by applicant]
US 7024312B1
· Selfinov et al.
· 2006
[cited by applicant]
US 7058515B1
· Selfinov et al.
· 2006
[cited by applicant]
US 7105297B2
· Minshull et al.
· 2006
[cited by applicant]
US 7148054B2
· delCardayre et al.
· 2006
[cited by applicant]
US 7288375B2
· Stemmer et al.
· 2007
[cited by applicant]
US 7421347B2
· Selfinov et al.
· 2008
[cited by applicant]
US 7430477B2
· Selfinov et al.
· 2008
[cited by applicant]
US 7531341B1
· Vellard et al.
· 2009
[cited by applicant]
US 7534564B2
· Patten et al.
· 2009
[cited by applicant]
US 7534595B2
· Vellard et al.
· 2009
[cited by applicant]
US 7560263B2
· Kakkis et al.
· 2009
[cited by applicant]
US 7620500B2
· Mundorff et al.
· 2009
[cited by applicant]
US 7620502B2
· Selfinov et al.
· 2009
[cited by applicant]
US 7629170B2
· delCardayre et al.
· 2009
[cited by applicant]
US 7702464B1
· Emig et al.
· 2010
[cited by applicant]
US 7747391B2
· Gustafsson et al.
· 2010
[cited by applicant]
US 7747393B2
· Fox
· 2010
[cited by applicant]
US 7751986B2
· Gustafsson et al.
· 2010
[cited by applicant]
US 7776598B2
· Patten et al.
· 2010
[cited by applicant]
US 7783428B2
· Gustafsson et al.
· 2010
[cited by applicant]
US 7795030B2
· Minshull et al.
· 2010
[cited by applicant]
US 7833742B2
· Treco et al.
· 2010
[cited by applicant]
US 7853410B2
· Selfinov et al.
· 2010
[cited by applicant]
US 7868138B2
· Stemmer et al.
· 2011
[cited by applicant]
US 7873499B2
· Selfinov et al.
· 2011
[cited by applicant]
US 7904249B2
· Selfinov et al.
· 2011
[cited by applicant]
US 7910545B2
· Meeker et al.
· 2011
[cited by applicant]
US 7957912B2
· Selfinov et al.
· 2011
[cited by applicant]
US 8383346B2
· Colbeck et al.
· 2013
[cited by applicant]
US 8504498B2
· Fox
· 2013
[cited by applicant]
US 8768871B2
· Fox
· 2014
[cited by applicant]
US 8849575B2
· Gustafsson et al.
· 2014
[cited by applicant]
US 8876066B1
· Richards
· 2014
[cited by applicant]
US 9308281B2
· Guild et al.
· 2016
[cited by applicant]
US 9593326B2
· Clark et al.
· 2017
[cited by applicant]
US 9909113B2
· Calhoun et al.
· 2018
[cited by applicant]
US 20080220990A1
· Fox
· 2008
[cited by applicant]
US 20090312196A1
· Colbeck et al.
· 2009
[cited by applicant]
US 20110280856A1
· Selden et al.
· 2011
[cited by applicant]
US 20130039898A1
· Okhamafe et al.
· 2013
[cited by applicant]
US 20150050658A1
· Cho
· 2015
[cited by applicant]
US 20150134315A1
· Sarmiento et al.
· 2015
[cited by applicant]
US 20170051267A1
· Calhoun
· 2017
[cited by applicant]
US 20170360900A1
· Agard et al.
· 2017
[cited by applicant]
US 20210269787A1
· Hallows et al.
· 2021
[cited by applicant]
JP 2001504324
· 2001
[cited by applicant]
JP 201352098A
· 2013
[cited by applicant]
WO 9522625A1
· 1995
[cited by applicant]
WO 9600787A1
· 1996
[cited by applicant]
WO 970078A1
· 1997
[cited by applicant]
WO 9735966A1
· 1997
[cited by applicant]
WO 9811206A2
· 1998
[cited by applicant]
WO 9827230A1
· 1998
[cited by applicant]
WO 200042651A1
· 2000
[cited by applicant]
WO 200175767A2
· 2001
[cited by applicant]
WO 2009152336A1
· 2009
[cited by applicant]
WO 2010144103A1
· 2010
[cited by applicant]
WO 2012170930A9
· 2012
[cited by applicant]
WO 2013156552A1
· 2013
[cited by applicant]
WO 2016105889A1
· 2016
[cited by applicant]
WO 2018132471A1
· 2018
[cited by applicant]
WO 2019125059A1
· 2019
[cited by applicant]
WO 2020132252A2
· 2020
[cited by applicant]
WO 2021026447A1
· 2021
[cited by applicant]
WO 2021173928A2
· 2021
[cited by applicant]
WO 2024042485A1
· 2024
[cited by applicant]
Advisory Action for U.S. Appl. No. 15/529,383, mailed on Jul. 30, 2020.
[cited by applicant]
Airaksinen, A. et al., “Modified base compositions at degenerate positions of a mutagenic oligonucleotide enhance randomness in site-saturation mutagenesis,” Nucleic Acids Res., vol. 26; 576-581 (1998).
[cited by applicant]
Final Office Action for U.S. Appl. No. 17/196,858, mailed Jun. 27, 2023.
[cited by applicant]
Final Office Action for U.S. Appl. No. 17/814,371, mailed on Feb. 20, 2024.
[cited by applicant]
Final Office Action for U.S. Appl. No. 15/529,383, mailed on May 18, 2020.
[cited by applicant]
Final Office Action for U.S. Appl. No. 16/985,761, mailed on Apr. 7, 2021.
[cited by applicant]
Final Office Action for U.S. Appl. No. 16/985,788, mailed on Feb. 14, 2022.
[cited by applicant]
Final Office Action for U.S. Appl. No. 17/186,462, mailed on Jan. 8, 2024.
[cited by applicant]
Genbank Accession No. BAD96347 dated Jul. 26, 2016.
[cited by applicant]
Goswami et al., “Gene Therapy Leaves a Vicious Cycle”, Front. One. 9:297, 2019, 25 pages (Year: 2019).
[cited by applicant]
Hideyuki Kobayashi, Koibuchi Research Report, vol. 29, pp. 3-12 (2013). Concise explanation met by submission of attached English translation of Japanese Office Action for Japanese Application No. 2022-078184, mailed Ju…
[cited by applicant]
International Preliminary Report on Patentability for PCT Patent Application No. PCT/US15/63329, mailed on Jul. 6, 2017.
[cited by applicant]
International Preliminary Report on Patentability for PCT Patent Application No. PCT/US19/67493, mailed on Jul. 1, 2021.
[cited by applicant]
International Preliminary Report on Patentability for PCT Patent Application No. PCT/US21/19811, mailed on Sep. 9, 2022, 7 pages.
[cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US15/63329, mailed on Jun. 3, 2016, 11 pages.
[cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US19/67493, mailed on Jun. 5, 2020, 11 pages.
[cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US21/19811, mailed on Aug. 17, 2021, 10 pages.
[cited by applicant]
Invitation to Pay Additional Fee received for PCT Patent Application No. PCT/US15/63329, mailed on Mar. 22, 2016, 2 pages.
[cited by applicant]
Invitation to Pay Additional Fee received for PCT Patent Application No. PCT/US19/67493, mailed on Mar. 19, 2020, 2 pages.
[cited by applicant]
Invitation to Pay Additional Fee received for PCT Patent Application No. PCT/US21/19811, mailed on Jun. 24, 2021, 2 pages.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 17/196,858, mailed Jul. 1, 2024.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 17/196,858, mailed Nov. 8, 2022.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 17/814,371, mailed on Jun. 28, 2023.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 16/985,742, mailed Sep. 2, 2020.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 15/529,383, mailed on Oct. 21, 2019.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 16/721,102, mailed on Nov. 5, 2021.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 16/985,761, mailed on Sep. 8, 2020.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 16/985,788, mailed on Oct. 21, 2021.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 17/186,462, mailed on Jan. 30, 2023.
[cited by applicant]
Notice for Allowance for U.S. Appl. No. 17/186,462, mailed on Jul. 8, 2024.
[cited by applicant]
Notice of Allowability for U.S. Appl. No. 16/985,742, mailed Mar. 16, 2021.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 17/196,858, mailed Jan. 31, 2024.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 17/196,858, mailed Oct. 18, 2023.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 17/814,371, mailed on Jun. 12, 2024.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 17/814,371, mailed on May 7, 2024.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 16/721,102, mailed on Apr. 22, 2022.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 16/985,742, mailed Dec. 7, 2020.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 16/985,761, mailed on Aug. 4, 2021.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 16/985,761, mailed on Nov. 23, 2021.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 16/985,788, mailed on Jul. 8, 2022.
[cited by applicant]
Qui, H., et al., “Impact of cysteine variants on the structure, activity, and stability of recombinant human alpha-galactosidase A,” The Protein Society, 24(9):1401-1411 [2015].
[cited by applicant]
Schultz, S.C. et al., “Site Saturation Mutagenesis of Active Site Residues of ß-Lactamase,” Proteins Structure and Function, pp. 521-528, Plenum Press, New York (1987).
[cited by applicant]
Siekierska, A. et al., “a-Galactosidase Aggregation Is a Determinant of Pharmacological Chaperone Efficacy in Fabry Disease Mutants,” J. Biol. Chem., vol. 287; 28386-28397 (2012).
[cited by applicant]
Singh et al., Curr. Protein Pept. Sci. 18:1-11, 2017 (Year: 2017).
[cited by applicant]
UniProt Database Accession No. A0A6P5ICW3, Jun. 2021, 2 pages (Year: 2021).
[cited by applicant]
UniProt Database Accession No. A0A6P6IS94, Jun. 2021, 2 pages (Year: 2021).
[cited by applicant]
UniProt Database Accession No. D5FGE4, Aug. 2017, 2 pages (Year: 2017).
[cited by applicant]
UniProt Database Accession No. F7BKN6, Aug. 2017, 2 pages (Year: 2017).
[cited by applicant]
Warren et al., UniProt Database, accession No. F715N7_CALJA, Jul. 2011.
[cited by applicant]
Yoshikatsu Eto, Journal of the Japanese Society of Internal Medicine, vol. 98, No. 4, pp. 163-170 (2009). Concise explanation met by submission of attached English translation of Japanese Office Action for Japanese Appl…
[cited by applicant]
Yoshimitsu, M. et al., “Sequencing and characterization of the porcine a-galactosidase A gene: towards the generation of a porcine model for Fabry disease,” Mol. Biol. Rep., vol. 38; 3145-3152 (2011).
[cited by applicant]
Zhang et al., Structure 26:1474-1485, 2018 (Year: 2018).
[cited by applicant]
Durant, B., et al., “Sex differences of urinary and kidneyglobotriaosylceramide and lyso-globotriaosylceramide in Fabry mice,” J. Lipid Res., 52:1742-6 [2011].
[cited by applicant]
Provencal, P., et al., “Relative distribution of Gb3 isoforms/analogsin NOD/SCID/Fabry mice tissues determined by tandem mass spectrometry,” Bioanal., 8(17):1793-1807 [2016].
[cited by applicant]
UniProt Accession No. P06280 dated Dec. 5, 2018.
[cited by applicant]
Sugawara, K., et al., “Structural characterization of mutant alpha-galactosidases causing Fabry disease,” J. Hum. Genet., 53(9):812-824 [2008].
[cited by applicant]
Ogawa et al., “Long-term inhibition of glycosphingolipid accumulation in Fabry model mice by a single systemic injection of AAV1 vector in the neonatal period”, Molecular Genetics and Metabolism, Academic Press, Amsterd…
[cited by applicant]
Altschul, S., et al., “Basic local alignment search tool,” J. Mol. Biol., 215: 403-410 [1990].
[cited by applicant]
Altschul, S.F., et al., “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs,” Nucleic Acids Res., 25(17):3389-3402 [1997].
[cited by applicant]
Beaucage, S.L., et al., “Deoxynucleoside phosphoamidites-A new class of key intermediates for deoxypolynucleotide synthesis,” Tetrahedron Letters, 22(20):1859-62 [1981].
[cited by applicant]
Black, M.E., et al., “Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy,” Proc Natl Acad Sci USA, 93:3525-3529 [1996].
[cited by applicant]
Botstein, D., et al., “Strategies and applications of in vitro mutagenesis,” Science, 229(4719):1193-1201 [1985].
[cited by applicant]
Caldwell, R.C., et al., “Mutagenic PCR,” PCR Methods Appl., 3:S136-S140 [1994].
[cited by applicant]
Carter, P., “Site-directed mutagenesis,” Biochem. J., 237:1-7 [1986].
[cited by applicant]
Christians, F.C., et al., “Directed evolution of thymidine kinase for AZT phosphorylation using DNA family shuffling,” Nat. Biotechnol., 17:259-264 [1999].
[cited by applicant]
Crameri, A., et al., “DNA shuffling of a family of genes from diverse species accelerates directed evolution”, Nature, 391:288-291 [1998].
[cited by applicant]
Crameri, A., et al., “Improved green fluorescent protein by molecular evolution using DNA shuffling,”Nat. Biotechnol., 14(3):315-319 [1996].
[cited by applicant]
Crameri, A., et al., “Molecular evolution of an arsenate detoxification pathway by DNA shuffling,” Nat. Biotechnol., 15 (5):436-438 [1997].
[cited by applicant]
Dale, S.J., et al., “Oligonucleotide-directed random mutagenesis using the phosphorothioate method,” Methods Mol. Biol., 57:369-74 [1996].
[cited by applicant]
Guo, Z., et al., “3′-End-Forming Signals of Yeast mRNA,” Mol. Cell. Biol., 15(11):5983-5990 [1995].
[cited by applicant]
Henikoff, S., et al., “Amino acid substitution matrices from protein blocks,” Proc. Natl. Acad. Sci., 89:10915-10919 [1992].
[cited by applicant]
Ikeda, K., et al., “Phenylalanine ammonia-lyase modified with polyethylene glycol: Potential therapeutic agent for phenylketonuria,” Amino Acids, 29:283-287 [2005].
[cited by applicant]
Kramer, B., et al., “Different base/base mismatches are corrected with different efficiencies by the methyl-directed DNA mismatch-repair system of
[cited by applicant]
Ling, M., et al., “Approaches to DNA Mutagenesis:An Overview,” Anal. Biochem., 254:157-78 [1997].
[cited by applicant]
Matthes, H.W.D., et al., “Simultaneous rapid chemical synthesis of over one hundred oligonucleotides on a microscale,” EMBO J., 3(4):801-05 [1984].
[cited by applicant]
McIlvaine, T.C., “A Buffer Solution for Colorimetric Comparison,” J. Biol. Chem., 49:183-186 [1921].
[cited by applicant]
Minshull, J., et al., “Protein evolution by molecular breeding,” Curr. Op. Chem. Biol., 3(3):284-290 [1999].
[cited by applicant]
Nance, C.S., et al., “Later-Onset Fabry Disease; An Adult Variant Presenting With the Cramp-Fasciculation Syndrome,” Arch. Neurol., 63:453-457 [2006].
[cited by applicant]
Needleman, S., et al., “A general method applicable to the search for similarities in the amino acid sequence of two proteins,” J. Mol. Biol. 48:443-453 [1970].
[cited by applicant]
Pearson, W.R., “Improved tools for biological sequence comparison,” Proc. Nat'l. Acad. Sci. USA, 85:2444-2448 [1988].
[cited by applicant]
Romanos, M.A., et al., “Foreign gene expression in yeast: a review,” Yeast 8:423-488 [1992].
[cited by applicant]
Schiffmann, R., “Fabry disease,” Pharm. Ther., 122:65-77 [2009].
[cited by applicant]
Smith, M., “In vitro mutagenesis,” Ann. Rev. Genet., 19:423-462 [1985].
[cited by applicant]
Smith, T., et al., “Comparison of Biosequences,” Adv. Appl. Math, 2:482-489 [1981].
[cited by applicant]
Southwood, S., et al., “Several Common HLA-DR Types Share Largely Overlapping Peptide Binding Repertoires,” J. Immunol., 160:3363-3373 [1998].
[cited by applicant]
Stemmer, W., “DNA Shuffling by Random Fragmentation and Reassembly: In vitro Recombination for Molecular Evolution,” Proc. Natl. Acad. Sci. USA, 91:10747-10751 [1994].
[cited by applicant]
Stemmer, W.P.C., “Rapid evolution of a protein in vitro by DNA shuffling”, Nature, 370:389-391 [1994].
[cited by applicant]
Vita, R., et al., “The Immune Epitope Database 2.0,” Nucl. Acids Res., 38(Database issue):D854-62 [2010].
[cited by applicant]
Wang, R.Y., et al., “Lysosomal storage diseases: Diagnostic confirmation and management of presymptomatic individuals,” Genet. Med., 13:457-484 [2011].
[cited by applicant]
Wells, J.A., et al., “Cassette mutagenesis: an efficient method for generation of multiple mutations at defined sites,” Gene, 34:315-323 [1985].
[cited by applicant]
Yasuda, K., et al., “Efficient and rapid purification of recombinant human α-galactosidase A by affinity column chromatography,” Prot. Exp. Pur,. 37(2):499-506 [2004].
[cited by applicant]
Zhang, J-H., et al., “Directed evolution of a fucosidase from a galactosidase by DNA shuffling and screening ,” Proc. Nat. Acad. Sci., U.S.A., 94:4504-4509 [1997].
[cited by applicant]
Zhao, H., et al., “Molecular evolution by staggered extension process (StEP) in vitro recombination,” Nat. Biotechnol., 16:258-261 [1998].
[cited by applicant]
UniProt Database Accession No. F1PFDO dated May 3, 2011.
[cited by applicant]
UniProt Database Accession No. J3S8S8 dated Oct. 31, 2012.
[cited by applicant]
UniProt Database Accession No. G1LPQ5 dated Oct. 19, 2011.
[cited by applicant]
Guce, A.I., et al., “Catalytic Mechanism of Human Alpha-Galactosidase”, J. Biological Chemistry, 285(6):3625-3634 [2010].
[cited by applicant]
GenBank Assession No. AAP36507.1 dated May 13, 2003.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 17/814,371, mailed Dec. 30, 2024.
[cited by applicant]